GlassScriptPhysician profile
Todd N Adkins
NPI 1629056502
$226,495.66
in general payments reported to CMS, 2019-2025
35 companies · $15K in 2025
The $15K reported for 2025 was more than what 90% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $19K · 2021: $27K · 2022: $65K · 2023: $70K · 2024: $21K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $92K · Food and Beverage: $9,778 · Consulting Fee: $2,275 · Travel and Lodging: $1,309 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $92,037.00 |
| Food and Beverage | $9,777.96 |
| Consulting Fee | $2,275.00 |
| Travel and Lodging | $1,309.19 |
| Education | $160.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $210,105.04 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $3,589.17 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,119.99 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $2,107.87 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Csl Behring | $1,888.53 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Genentech USA, INC. | $1,417.95 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $1,262.04 | 2019-2025 | |
| Pfizer INC. | $567.76 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $520.51 | 2020-2025 | Hyqvia, Eohilia, Cuvitru |
| Amgen INC. | $388.66 | 2021-2025 | Tezspire |
| Grifols USA, LLC | $351.85 | 2020-2025 | Prolastin-C Liquid, Xembify |
| Abbvie INC. | $331.77 | 2021-2023 | Rinvoq |
| Octapharma USA, INC. | $245.81 | 2023-2025 | Panzyga, Octagam Immune Globulin (Human), Cutaquig |
| Pharming Healthcare, INC. | $201.66 | 2019-2025 | Ruconest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.42 | 2019-2023 | Spiriva Respimat |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $168.25 | 2019-2021 | |
| Leo Pharma INC. | $155.69 | 2022-2025 | Anzupgo, Adbry |
| Ionis Pharmaceuticals, INC. | $143.80 | 2025 | Dawnzera |
| Shire North American Group INC | $123.65 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $110.31 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $97.25 | 2021-2023 | |
| Optinose US, INC. | $69.37 | 2019-2024 | |
| Ars Pharmaceuticals Operations, INC. | $66.68 | 2025 | Neffy |
| Insmed, INC. | $39.48 | 2025 | Brinsupri, Arikayce |
| Qol Medical, LLC | $39.44 | 2024 | Sucraid |
| Biocryst US Sales Co., LLC | $38.73 | 2025 | Orladeyo |
| Blueprint Medicines Corporation | $33.69 | 2024 | Ayvakit |
| Biocryst Pharmaceuticals, INC. | $25.06 | 2020 | |
| Mylan Specialty L.P. | $17.59 | 2020 | |
| Philips North America LLC | $14.91 | 2021 | |
| Organon LLC | $14.80 | 2025 | |
| Phathom Pharmaceuticals, INC. | $14.36 | 2024 | Voquezna |
| Lilly USA, LLC | $14.19 | 2025 | Ebglyss |
| Cycle Pharmaceuticals INC | $13.87 | 2025 | Sajazir |
| Incyte Corporation | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Adkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.